Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

Fast track designation is an FDA status reserved for products that are intended to treat a serious or life-threatening condition and that demonstrate the potential to address unmet medical needs for that condition. Fast track designation can potentially facilitate development and expedite the review process.

"Our receipt of fast track designation for dirucotide in the U.S. is a significant milestone for both BioMS Medical and the MS community," said Kevin Giese, President and CEO of BioMS Medical. "Based on previous clinical results, we believe dirucotide is well-positioned to become a first-in-class treatment for secondary progressive MS patients, a large patient population with very limited treatment options."

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About Diruc
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...acy endpoint has been met for patients with advanc..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - A...he "Company"), a global biopharmaceutical company ...nnounced positive efficacy data from a Phase 2 stu...AEZS-108 (formerly AN-152), in patients with advan...
(Date:11/24/2009)... 24, 2009 Arena Pharmace...hat the company is scheduled to present at the Pip...ecember 1, 2009 at 11:30 a.m. Eastern Time (8:30 a...New York City. Jack Lief, Arena,s President and Ch...overview of the company, including its clinical de...
(Date:11/24/2009)...am Connects Customers with Partners Validated to P...tek Products , Ottawa, ON...ding provider of products for biological sample co...ounced its new global partner program. The program... partner community and is designed to help partner...
(Date:11/23/2009)...9 In a provocative new study, a University of Uta...sions the major cause of global warming cannot b...or society builds the equivalent of one new nuclea...at there will be any substantial near-term departu...ioxide emission rates," says the new paper by Tim ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...6 Zounds Hearing, a unique manufacturing,and reta...th state-of-the-art,fidelity, price point and prof...sistive listening devices (ALDs) in an effort to a...s are now available in all of the Zounds Hearing,C...8. And, from November 26,2008, through December 7...
... 26 Ceregene, Inc., a biopharmaceutical,company, ...controlled Phase 2,trial of CERE-120 in 58 patient...d not demonstrate an appreciable difference betwee...he control group. Both groups showed an approximat...ary endpoint (Unified,Parkinson,s Disease Rating S...
...Nov. 26 Covaris Incorporated today,announced that... the shipment,of its 500th instrument unit and con...o accommodate this rapid business growth, Covaris ...nization as well as implementing a,50% expansion o...was built upon the proprietary and patented AFA(TM...
Other Biology Technology:Zounds Offers the Gift of Hearing This Holiday Season With a Range of New Products 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 2Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease 3Covaris Installed Instrument Base Reaches 500 Units 2
(Date:11/25/2009)...Kent State University assistant professors recentl...ation (NSF) to continue research beneficial to und... $890,000. , Christopher Blackwood, assistant pr...was awarded grants to support two separate researc...ing Litter Decomposer Communities and Functions fr...
(Date:11/24/2009)...Lupus Research Institute (LRI) today named 12 new ....6 million, recognize innovative work across a bro...or their creativity, novelty, and potential to dri...at, and cure the complex disease of systemic lupus...ed lupus researchers across the nation and include...
(Date:11/24/2009)...ts that keep weakened and flabby arteries from col...months, those stents are no longer needed -- once ...sary. Previously, doctors had no choice but to lea...l Aviv University,s Department of Biomedical Engin...atform that carries drugs where they,re needed, th...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A coating for life 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
...uman immunodeficiency virus (HIV-1) molecular mach...functionally-specialized layers, according to a st...ia San Diego (UCSD) Antiviral Research Center (AVR...ology. , The unprecedented genetic diversity an... efforts to eradicate the global HIV/AIDS epidemic...
...uld More Than Double its Current Revenue, Stream...care Industry, SAN JOSE, Calif., Nov. 2 Titanium...ing biometric and security,solutions provider, ann...tent to acquire China Medical Systems (OTC: CHSY),...ching, developing and marketing of specialized,sof...
...d streams in remote parts of the UK, southern Scan...singly stained brown by dissolved organic matter. ...rnational team, led by researchers from UCL (Unive...tection Agency (EPA), demonstrates that the colour...l, pre-industrial state following a decline in the...
Other Biology News:Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 2Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 3Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network 4Don't judge a brook by its color -- brown waters are more natural 2
...Adept CE 4100 high pressure dual piston pumps, eac...nts. The ground breaking WaveQuest UV/Visible ult...ity. The WaveQuest provides a trustworthy altern... superior stability . Hence only one detector is ...
...ples may be carried out using this high pressure s...System control and data processing is provided by ...legant, powerful and very easy to use software ope... supplied detector is the ground breaking WaveQues...
Oligonucleotides from Thermo Scientific
Pyrex brand low actinic narrow mouth Erlenmeyer flask, Pyrex ST 27 stopper from Sigma-Aldrich
Biology Products: